NeuroMetrix Inc. (NASDAQ: NURO) To Use Quell Technology in Studying TENS in NMSOD patients

NeuroMetrix Inc. (NASDAQ: NURO) has announced they will use Quell tech in a randomized double-blinded, sham-controlled study to establish that transcutaneous electrical nerve stimulation (TENS) is an acceptable, feasible, and effective pain relief method in NMOSD patients. Michael Levy, the director, NMO Clinical & Research laboratory, Massachusetts General Hospital, will be the study’s principal investigator. 

NMSOD can lead to vision loss and paralysis 

NMSOD is a chronic relapsing autoimmune disease that is rare, and it affects the CNS targeting the spinal cord and optic nerves. It can lead to paralysis or vision loss. In most cases, central neuropathic pain is characterized by shooting/tingling sensation and chronic burning in the legs, arms, and torso. CNP is debilitating, and available treatments’ efficacy is limited. 

TENS  is a non-pharmacological pain relief treatment that has demonstrated efficacy in neuropathic pain, but it’s yet to be evaluated in NMOSD. Notably, Quell tech is an advanced TENS platform that offers precise, flexible, and high-power nerve simulation wearables. 

Shai N. Gozani, the NeuroMetrix CEO, said, “ We are pleased to support Dr. Levy and his colleagues in this clinical trial. NMOSD is a disabling disease without safe and effective treatment options. This rigorous randomized controlled trial will add to the growing body of clinical data on the utility of Quell technology in chronic pain conditions with a neuropathic pain component. There are significant unmet clinical needs in the treatment of neuropathic pain that Quell may be able to eventually address.”

NeuroMetrix releases Quell study in fibromyalgia patients. 

Recently the company released topline results from a controlled study of Quell in fibromyalgia patients, which will be presented at upcoming pain medicine conferences. The randomized, double-blind, sham-controlled study was carried at the Centre for pain management, Bingham and Women’s Hospital. The study enrolled 119 fibromyalgia patients who were randomized to a standardized and sham Quell device for three months of at-home use.